The report analyzes and presents an overview on "The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities" worldwide.

1. The Oncolytic Virus Landscape 2017: an analysis of pipeline,
stakeholders, deals, industry trends & opportunities
The report analyzes and presents an overview on "The Oncolytic Virus Landscape
2017: an analysis of pipeline, stakeholders, deals, industry trends &
opportunities" worldwide.

2. The field of oncolytic viruses was quite dormant in the first decade of the 2000s,
characterized by slow clinical progress due to hypercautiousness and low, albeit steady,
investments. The takeover of BioVex by Amgen in late 2011, worth up to US$ 1 bln, has
woken up the field and became a game changer together with the 2015 approval of the
first oncolytic virus Imlygic developed by BioVex in regulated markets. In addition, it was
increasingly recognized that oncolytic viruses not only were able to directly lyse cancer
cells, but they also „freed“ tumor specific neoantigens, indirectly acting as a cancer
vaccine.
However, the efficacy of oncolytic viruses still was modest, but can be improved when
combined with immune checkpoint inhibitors. This lead to an increased partnering interest
of the major immuno-oncology (I-O) players, but also of investors who view oncolytic
viruses as a must be for I-O combination regimens. As a consequence, total venture equity
and private investments into oncolytic virus companies in 2016 was nearly 17-fold higher
than in the year 2010.

3. Optimization of oncolytic viruses is ongoing and new constructs intend to solve some of
the open problems regarding the way of administration (intratumoral vs systemic), higher
cancer cell specific replication capacity, and longer persistence in vivo. Based on
experience with several virus families over the last decades, a few virus families
cristallized as well suitable backbones to carry more and more transgenes to express
proteins or even single chain antibodies. This would position oncolytic viruses as
independent therapeutics and could compete with immuno-oncology compounds and
cancer vaccines.
Get The Sample Copy Of This Report:
http://www.marketresearchreports.biz/sample/sample/943738
This report „The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders,
deals, industry trends & opportunities“ as of January 2017 brings you up-to-date regarding
key players, key technologies, Oncolytic Virus projects, business deals and private and
public financing rounds. The report analyzes the Oncolytic Virus pipeline and stakeholders
in the field, especially among Big Pharma/Biotech and technology companies. The report

4. highlights the value of oncolytic viruses in terms of partnering terms and conditions,
venture and private financing and (initial) public offerings.
Table of Contents
1 Executive Summary
2 Introduction & Overview
3 Selection, Design & Construction of Oncolytic Viruses
3.1 Herpes Simplex Virus (HSV) – based Oncolytic Viruses
3.2 Adenoviruses – based Oncolytic Viruses
3.3 Vaccinia Virus - Based Oncolytic Viruses
3.4 Vesicular Stomatitis Virus - based Oncolytic Viruses
3.5 Newcastle Disease Virus - based Oncolytic Viruses
3.6 Various Oncolytic Viruses

5. 4 Profiles of Oncolytic Viruses
4.1 HSV-based Oncolytic Viruses
4.1.1 Imlygic; talimogene laherparepvec; T-Vec; OncoVEX(GM-CSF)
4.1.2 G47?
4.1.3 HF10; TB-1401
4.1.4 HSV1716; seprehvir
4.1.5 HSV-Rb-p450
4.1.6 BV-2711
4.1.7 ONCR-001
4.2 Adenovirus-based Oncolytic Viruses
4.2.1 Oncorine
4.2.2 CG0070
4.2.3 DNX-2401
4.2.4 OBP-301; telomelysin
4.2.5 ONCOS-102
4.2.6 Enadenotucirev; ColoAd1
4.2.7 Adenoviral VirRx 007; INGN 007; VRX-007

6. 4.2.8 VCN-01
4.2.9 LOAd703
4.2.10 H103
4.2.11 NG-348
4.2.12 ORCA-010
4.2.13 TILT-123
4.2.14 UIO-112
4.2.15 TILT-324
4.2.16 DNX-2440; Delta-24-RGDOX
4.2.17 DNX-2450
4.2.18 OBP-702
4.3 Vaccinia Virus-based Oncolytic Viruses
4.3.1 Pexastimogene devacirepvec; Pexa-Vec; JX-594; TG6006
4.3.2 GL-ONC1
4.3.3 JX-929; vvDD
4.3.4 TG6002
4.3.5 WO-12

7. 4.4 Vesicular Stomatitis Virus-based Oncolytic Viruses
4.4.1 MG1 Maraba/MAGE-A3 (MG1MA3)
4.4.2 VSV-IFNbeta
4.4.3 VSV-IFNbeta-NIS
4.4.4 VSV-GP
4.5 Newcastle Disease Virus-based Oncolytic Viruses
4.5.1 NDV-HUJ
4.5.2 PV701
4.5.3 recNDVGM-CSF
4.6 Various Oncolytic Viruses
4.6.1 Rigvir
4.6.2 Reolysin; pelareorep
4.6.3 CAVATAK; CVA21
4.6.4 MV-NIS
4.6.5 NTX-010; SVV-001
4.6.6 H-1PV
4.6.7 PVS-RIPO

8. 4.6.8 MYX-135
4.7 Stem Cell-delivered Oncolytic Viruses
4.7.1 TBX.OncV (CRad-Survivan-pk7)
4.7.2 MSC-ICOVIR-5
5 Analysis of Oncolytic Virus Pipeline
5.1 Overview of the Pipeline of Oncolytic Viruses
5.2 Approved and Marketed Oncolytic Viruses
5.3 Late Stage Development of Oncolytic Viruses
5.4 Combination of Oncolytic Viruses with Immune Checkpoint Inhibitors and Other Anti-
Tumor Agents
5.5 Armed Oncolytic Viruses
About us
MarketResearchReports.biz is the most comprehensive collection of market
research reports. MarketResearchReports.Biz services are specially designed to

9. save time and money for our clients. We are a one stop solution for all your
research needs, our main offerings are syndicated research reports, custom
research, subscription access and consulting services. We serve all sizes and types
of companies spanning across various industries.
To View The Top Related News:
http://www.marketresearchreports.biz/articles
Contact US:
Office: United States

10. State Tower
90 State Street, Suite 700
Albany, NY 12207
United States
Toll Free: 866-997-4948
Tel: +1-518-618-1030
E: sales@marketresearchreports.biz